Quantum Biopharma (QNTM) Gains from Sales and Divestitures (2025)
Quantum Biopharma's (QNTM) quarterly Gains from Sales and Divestitures came in at -$175194.0 in Q3 2025.
Powered by 
Analysis
Quantum Biopharma (QNTM) Gains from Sales and Divestitures (2025) Analysis & Trends
Quantum Biopharma has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting -$175194.0 for Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Quantum Biopharma | 12.60 Mn | 7.09 Mn | - |